An expanded access programme for prior and concurrent use of abiraterone and enzalutamide with Ra-223

Trial Profile

An expanded access programme for prior and concurrent use of abiraterone and enzalutamide with Ra-223

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Sep 2015

At a glance

  • Drugs Radium 223 chloride (Primary) ; Abiraterone; Enzalutamide
  • Indications Prostate cancer
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2015 Safety and overall survival results will be presented at the 2015 European Cancer Congress, according to Bayer media release.
    • 26 Feb 2015 New trial record
    • 23 Feb 2015 According to a Bayer HealthCare Pharmaceuticals media release, data from this study will be presented at the 2015 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top